Tipranavir

Tipranavir
Systematic (IUPAC) name
N-{3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3,4-dihydro-2H-pyran-5-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
Clinical data
Trade names Aptivus
AHFS/Drugs.com monograph
MedlinePlus a606009
License data
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration
Oral
Legal status
Legal status
Pharmacokinetic data
Bioavailability N/D
Protein binding 99.9%
Metabolism Hepatic
Biological half-life 4.8–6 hours
Excretion Feces (82.3%), urine (4.4%)
Identifiers
CAS Number 174484-41-4 YesY
ATC code J05AE09 (WHO)
PubChem CID 65027
DrugBank DB00932 YesY
ChemSpider 10482313 YesY
UNII ZZT404XD09 YesY
ChEMBL CHEMBL183041 N
NIAID ChemDB 032941
PDB ligand ID TPV (PDBe, RCSB PDB)
Chemical data
Formula C31H33F3N2O5S
Molar mass 602.66 g/mol
 NYesY (what is this?)  (verify)

Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer-Ingelheim under the trade name Aptivus. It is administered with ritonavir in combination therapy to treat HIV infection.

Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.[1]

Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.[2] Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, side effects of tipranavir may be more severe than those of other anti-retrovirals. Some side effects include intracranial hemorrhage, hepatitis, hyperglycemia and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.[3]

References

  1. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley M (2005). "Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.". Antiviral Res 68 (1): 2735. doi:10.1016/j.antiviral.2005.07.003. PMID 16122817.
  2. "New Aptivus (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients" (Press release). Boehringer Ingelheim. 2008-06-24. Retrieved 2008-09-02.
  3. "Aptivus® (tipranavir) capsules 250 mg, oral solution 100 mg/mL, Prescribing Information", Boehringer Inhelheim, 2012. Revised April 2012.
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.